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Peptide substratea b s t r a c t
Botulinum neurotoxins (BoNTs) produced by Clostridium botulinum are the most poisonous substances
known to humankind. It is essential to have a simple, quick, and sensitive method for the detection
and quantiﬁcation of botulinum toxin in various media, including complex biological matrices. Our lab-
oratory has developed a mass spectrometry-based Endopep–MS assay that is able to rapidly detect and
differentiate all types of BoNTs by extracting the toxin with speciﬁc antibodies and detecting the unique
cleavage products of peptide substrates. Botulinum neurotoxin type E (BoNT/E) is a member of a family of
seven distinctive BoNT serotypes (A–G) and is the causative agent of botulism in both humans and
animals. To improve the sensitivity of the Endopep–MS assay, we report here the development of novel
peptide substrates for the detection of BoNT/E activity through systematic and comprehensive
approaches. Our data demonstrate that several optimal peptides could accomplish 500-fold improvement
in sensitivity compared with the current substrate for the detection of both not-trypsin-activated and
trypsin-activated BoNT/E toxin complexes. A limit of detection of 0.1 mouse LD50/ml was achieved using
the novel peptide substrate in the assay to detect not-trypsin-activated BoNT/E complex spiked in serum,
stool, and food samples.
Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/3.0/).The neurotoxins produced by Clostridium botulinum (botulinum
neurotoxins, BoNTs)1 are the most poisonous substances known to
humankind. The life-threatening diseases caused by these toxins
include food-borne botulism, infant botulism, wound botulism, and
adult intestinal colonization [1]. BoNTs also constitute a potential
biological weapon because they are easy to produce [2]. On the other
hand, botulinum toxins have been used for therapeutic or aesthetic
applications [3]. For all of these applications, it is essential to have
a simple, quick, and sensitive method for the detection and quanti-
ﬁcation of botulinum toxin in various media, including complex
biological matrices.
The botulinum neurotoxins are synthesized as single-chain
polypeptides of 150 kDa that undergo proteolytic cleavage to gen-
erate active holotoxins composed of two protein subunits linked bya disulﬁde bond: a heavy chain (100 kDa) involved in target
binding and a light chain (50 kDa) responsible for the toxicity
through its peptidase activity [4]. In fact, the BoNTs belong to a
family of zinc-dependent metallopeptidases. They cleave neuronal
proteins involved in the exocytosis of neurotransmitters, such as
SNAP-25 (25-kDa synaptosomal protein), synaptobrevin, and syn-
taxin, at the site speciﬁc to each toxin [5,6]. This cleavage conse-
quently blocks the release of neurotransmitter molecules at the
neuromuscular junction, ultimately leading to ﬂaccid paralysis of
muscle activity.
The botulinum neurotoxin type E (BoNT/E) forms part of a fam-
ily of seven conﬁrmed related serotypes (botulinum neurotoxins
A–G) produced by different strains of C. botulinum [7]. BoNT/E is
a neurotoxin that causes botulism in both humans and animals.
The most common intoxication by toxin type E is associated with
eating contaminated ﬁsh [8,9]. BoNT/E is unique because it is
released from the bacterium as a single chain and cleaved into
an active di-chain form by unidentiﬁed host cell proteases or other
exogenous proteases such as trypsin [10,11]. Activation of a single-
chain BoNT/E by trypsin leads to an approximately two orders of
magnitude more potent neurotoxin than the single-chain molecule
[10,12].
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botulinum toxins [2]. It is very sensitive, detecting as little as
approximately 10 pg of active toxin, which is deﬁned as 1 mouse
LD50 (mLD50), but the assay can be slow in obtaining ﬁnal results
and requires the sacriﬁce of many animals. Therefore, much effort
has been undertaken to develop alternative in vitro endopeptidase
activity assays based on BoNTs’ intrinsic enzymatic function.
Several laboratories, including ours, have developed activity meth-
ods by measuring the BoNTs’ cleavage products using synthetic
peptide substrates with various detection platforms [13].
BoNT/E speciﬁcally cleaves one of the SNARE (SNAP receptor)
complex proteins, SNAP-25, at the Arg180–Ile181 bond [14].
Montecucco and coworkers revealed that the minimal length for
proteolysis of SNAP-25 by BoNT/E includes a SNARE motif starting
from Ala141 [15]. Binz and coworkers deﬁned the minimal
essential domain of SNAP-25 required for cleavage by BoNT/E as
Ile156–Asp186 [16]. Through saturation mutagenesis and deletion
mapping, Barbieri and Chen deﬁned a short optimal cleavage
domain of Met167–Asp186, where the subsite of Met167–Thr173
was considered as a binding domain contributing to substrate
afﬁnity [17,18]. These ﬁndings led to the development of peptide
substrates used in various in vitro activity assay platforms for the
detection of the BoNT/E toxin. For instance, a ﬂuorescence-based
assay uses a recombinant substrate consisting of the SNAP-25
sequence Ile134–Gly206 ﬂanked by a green ﬂuorescent protein
(GFP) and a blue ﬂuorescent protein (BFP) [19]. A 70-mer peptide
of Val137–Gly206 as a substrate is included in an immunoassay
where the cleavage product was detected by a speciﬁc antibody
[20]. The sequence of Ala141–Gly206 with a ﬂuorescent tag on
either terminus of the peptide formed a substrate included in the
BoTest kit that uses Förster resonance energy transfer (FRET) tech-
nology to detect BoNT/E activity [21]. A 61-mer peptide comprising
the sequence of Met146–Gly206 is reported in a capillary electro-
phoresis method [22]. The peptides of Ile156–Asp186 and Ile156–
Thr190 are used in a mass spectrometry (MS)-based Endopep–MS
assay developed in our laboratory [23,24]. During the preparation
of this study, a new article published claimed that the peptide of
Met167–Asp186 and its derivative with two Met residues replaced
by Nle residues were effective substrates for the Endopep–MS
platform [25]. This report described the development of a novel
peptide substrate to improve the sensitivity of the Endopep–MS
assay for the determination of BoNT/E catalytic activity. Through
comprehensive optimization using approaches of truncation, dele-
tion, single and multiple substitution, and other modiﬁcations, we
have developed several highly efﬁcient peptides that showed a
more than 500-fold improvement over the substrate currently
used in the Endopep–MS assay.Materials and methods
All chemicals were obtained from Sigma–Aldrich (St. Louis, MO,
USA) except where indicated otherwise. Fmoc–amino acid deriva-
tives and peptide synthesis reagents were purchased from EMD
Chemicals (Gibbstown, NJ, USA) or Protein Technologies (Tucson,
AZ, USA). Isotopically labeled Fmoc–amino acid derivatives were
purchased from Cambridge Isotope Laboratories (Tewksbury, MA,
USA). The complex forms of the botulinum neurotoxin without
preactivation and the trypsin-activated BoNT/E toxin were
obtained from Metabiologics (Madison, WI, USA). Botulinum neu-
rotoxin is highly toxic, and appropriate safety measures are
required. All BoNTs were handled in a class 2 biosafety cabinet
equipped with HEPA ﬁlters. Monoclonal antibodies were provided
by James Marks at the University of California, San Francisco.
Streptavidin-coated Dynabeads were purchased from Invitrogen
(Lake Success, NY, USA). Serum and stool extracts were purchasedfrom commercial sources or collected from anonymous donors,
and no demographic information was obtained (Centers for
Disease Control and Prevention institutional review board 4307).
Peptide synthesis
All peptides were prepared in-house by a solid-phase peptide
synthesis method using Fmoc chemistry on a Liberty microwave
peptide synthesizer (CEM, Matthews, NC, USA) or a Tribute peptide
synthesizer (Protein Technologies). Peptides were cleaved and
deblocked using a reagent mixture of 95% triﬂuoroacetic acid
(TFA)/2% water/2% anisole/1% ethanedithiol and puriﬁed by
reversed-phase high-performance liquid chromatography (HPLC)
using a water/acetonitrile/0.1% TFA gradient (90–95% purity). Cor-
rect peptide structures were conﬁrmed by matrix-assisted laser
desorption/ionization (MALDI)–MS. All peptides were dissolved
in deionized water as a 1-mM stock solution and were stored at
70 C until further use.
Endopep–MS assay
In-solution or on-bead Endopep–MS assays were carried out as
described previously [26]. In brief, the reaction was conducted in a
20-ll reaction volume containing 0.1 mM peptide substrate,
10 lM ZnCl2, 1 mg/ml bovine serum albumin (BSA), 10 mM dithio-
threitol, and 200 mMHepes buffer (pH 7.4) at 37 C for 1 or 4 h. For
the in-solution assays without antibody-coated beads, various con-
centrations of BoNT/E, as indicated in the text, were directly added
into the reaction mixture. For samples including complex matrices,
the toxin spiked in matrix was ﬁrst puriﬁed by antibodies immobi-
lized on streptavidin beads followed by an activity assay as
described previously [26].
After reaction, 2 ll of the supernatant was mixed with 20 ll of
a-cyano-4-hydroxycinnamic acid at 5 mg/ml in 50% acetonitrile/
0.1% TFA/1 mM ammonium citrate, and then 2 ll of a 1-lM inter-
nal standard peptide (isotope-labeled peptides resembling the
sequence of either the C- or N-terminal cleavage product) was
added to the solution. The formation of cleavage products was
measured as the ratio of the isotope cluster areas of the cleavage
product versus an internal standard.
MS detection
Each sample was spotted in triplicate on a MALDI plate and ana-
lyzed on a 5800 MALDI–TOF (time-of-ﬂight)–MS instrument
(Applied Biosystems, Framingham, MA, USA). Mass spectra of each
spot were obtained by scanning from 800 to 4000 m/z in MS-
positive ion reﬂector mode. The instrument uses an Nd-YAG laser
at 355 nm, and each spectrum is an average of 2400 laser shots.Results and discussion
Optimal length of peptide substrate of BoNT/E determined by
truncation, deletion, and mutation
Endopep–MS assay is a method using mass spectrometry,
matrix-assisted laser desorption/ionization, or electrospray ioniza-
tion to detect either one or two cleavage products hydrolyzed from
a peptide substrate by an afﬁnity-enriched toxin. Therefore, assay
sensitivity not only will depend on the hydrolysis efﬁciency (sub-
strate binding and catalysis) but also will rely on the ionization
of cleaved peptide fragments, which is associated with their amino
acid sequence. Although different lengths of peptides including the
essential elements for substrate binding and cleavage are applied
in various in vitro BoNT activity assays as described above, a study
Table 1
Hydrolysis of N- or C-terminal truncated peptide substrates by BoNT/E toxin.
aRelative cleavage rate obtained from the analysis of C-terminal cleavage products (CT prod). Conditions: 37 C, 4 h.
bRelative cleavage rate obtained from the analysis of N-terminal cleavage products (CT prod).
cThe cleavage site of BoNT/E substrate is depicted in bold.
dPep-8 is the BoNT/E substrate currently used in Endopep–MS assay.
Table 2
Relative production of N- or C-terminal product cleaved from truncated or modiﬁed peptide substrates by BoNT/E toxin.
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detection of BoNT/E by Endopep–MS was lacking. The peptide sub-
strate (Pep-8 in Table 1) currently used in the Endopep–MS assay
was derived from the partial sequence of SNAP-25, ranging from
the amino acid residue Ile156 to Thr190 [27]. To examine whether
further improvement can be achieved by optimizing peptide length
for our Endopep–MS assay, we systematically prepared a series of
peptides with extended or shortened sequences from either the N-
or C-terminal direction of Pep-8, where the opposite end of the
substrate remained the same (Table 1). To avoid bias caused by
sequence-dependent ionization of cleavage fragments, the hydro-
lysis of the peptides with variable N termini (Pep-1 to Pep-6)
was compared by measuring the formation of C-terminal cleavage
products by MALDI–TOF–MS, whereas the hydrolysis of the C-ter-
minal varied peptides (Pep-7 to Pep-14) was compared with the
production of N-terminal cleavage products. For those N-terminal
truncated peptides, the longest peptide (Pep-1) with the SNAP-25
sequences of Ala141–Gly206 yielded the highest production of
the cleavage product. When 10 or 15 N-terminal residues were
removed (Pep-2 and Pep-3), the cleavage efﬁciency of these two
substrates underwent a slight decrease. On the other hand, further
deleting N-terminal resides (Pep-4 to Pep-6) led to a drastic reduc-
tion or nondetection of the cleavage products. For C-terminal trun-
cated peptides, extending amino acid residues all the way to thelast SNAP-25 residue at the position 206 (Pep-7) did not provide
any beneﬁt compared with the activity of Pep-8 substrate, which
ends at position 190. Further C-terminal truncation of the peptides
caused a steady decrease in their substrate hydrolysis (Pep-9 to
Pep-14). In summary, Pep-1 performed the best among the tested
BoNT/E substrate peptides of various lengths. This likely explained
why the peptide itself, or with added ﬂuorescence tags, was used
as an efﬁcient substrate in other studies and commercial kits
(BoTest A/E Botulinum Neurotoxin Detection Kit, Biosentinel).
The large size of this peptide (7.5 kDa), however, raised issues such
as difﬁculty of peptide preparation and low solubility in assay buf-
fers. In contrast, the molecular weight of Pep-8 (4.0 kDa) is nearly
half that of Pep-1, but it has retained 90% of the substrate activity.
For these reasons, we decided to use this peptide as a template for
further optimization.
The next modiﬁcation to optimize the substrate focused on
adding or deleting single amino acids to or from either end of Pep-
8 in order to examinewhether smaller changes in peptide size affect
the substrate activity. As shown in Table 2, removing one or two Ile
residues from the N terminus of the peptide resulted in a 30% to 40%
decrease in cleavage efﬁciency of the newly formed peptides (Pep-
15 and Pep-16). In addition, extending the sequence (Pep-17) by
adding a glycine (residue 155 of SNAP-25) to the N terminus led
to reduced production of enzyme cleavage products as well. The
Table 3
Relative production of the N- or C-terminal product cleaved from internally deleted peptides by BoNT/E toxin.
Peptide Sequence CT product (%) NT product (%)
Pep-20 IIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTR 100
Pep-22 IIIGNLRHMALDMGNE_____RQIDRIMEKADSNKTR 6
Pep-23 IIIGNLRHMAL_____IDTQNRQIDRIMEKADSNKTR 17
Pep-24 IIIGNL_____DMGNEIDTQNRQIDRIMEKADSNKTR 90
Pep-25 IIIGN_____DMGNEIDTQNRQIDRIMEKADSNKTR 19
Pep-26 IIIG_____DMGNEIDTQNRQIDRIMEKADSNKTR 43
Pep-27 III_____DMGNEIDTQNRQIDRIMEKADSNKTR 30
Pep-28 IIIGNL_____NEIDTQNRQIDRIMEKADSNKTR 2
Pep-29 IIIGNL_____GNEIDTQNRQIDRIMEKADSNKTR 88
Pep-30 IIIGNL_____MGNEIDTQNRQIDRIMEKADSNKTR 33
Pep-31 IIIGNL_____LDMGNEIDTQNRQIDRIMEKADSNKTR 53
Pep-29 IIIGNL_____GNEIDTQNRQIDRIMEKADSNKTR 88 100
Pep-32 IIIGNL_____GNEIDTQNRQIDRIMEKADSNKR 117 136
Pep-33 IIIGNL_____GNEIDTQNRQIDRIMEKADSNR 91 84
Pep-34 IIIGNL_____GNEIDTQNRQIDRIMEKADSR 18 36
Note. Deleted amino acid residues from Pep-20 are depicted by underscore.
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ulate that the side chains of these two Ile residues might have some
direct contact with the enzyme through a hydrophobic–hydropho-
bic interaction. An increase in the cleavage product from Pep-18,
after the third Ile residue was incorporated into the N terminus of
Pep-8, provided some supportive evidence for this hypothesis.More
studies attempting to address this issue are described below.
A remarkable improvement was obtained when one or two
additional SNAP-25 residues were extended on the C terminus of
Pep-18. Incorporation of Arg191 and Arg191–Ile192 into Pep-19
and Pep-20, respectively, resulted in a 20-fold increase in the detec-
tion of the C-terminal cleavage products (CT products) (Table 2).
Because the N-terminal products (NT products) cleaved from these
peptides did not show signiﬁcant changes, the elevated measure-
ment of the CT product should not come from altered cleavage efﬁ-
ciency of the new substrates but rather must be due to the
contribution of elevated ionization efﬁciency of the CT products
measured in positive ion mode by MALDI–TOF–MS, presumably
directly associated with a positively charged Arg residue. In con-
trast, deletion of two C-terminal residues containing a positively
charged lysine from Pep-18 led to a peptide (Pep-21) with reduced
cleavage efﬁciency, indicated by a 52% production of the NT product
and decreased ionization of its CT product (20%) as well.
In an attempt to shorten peptide size to improve synthesis yields
and/or peptide solubility in the reaction buffer, internal deletions
were applied on the N-terminal portion of the new template pep-
tide, Pep-20. Table 3 shows that three peptides (Pep-22, Pep-23,
and Pep-24) deleting ﬁve consecutive residues in different regions
yielded different consequences. Whereas less than 20% of the CT
product was detected from Pep-22 and Pep-23, removal of the area
consisting of the sequence of RHMAL in Pep-24 retained 90%
substrate activity, revealing that the chain of RHMAL did not play
a critical role in peptide binding and/or substrate cleavage. Further
deleting several residues sequentially, ﬂanking either end of this
ﬁve-residue region, produced seven new peptides, Pep-25 to
Pep-31. Among these peptides, Pep-29, with two more residues
removed, maintained a relative production of the CT product
(88%) similar to that of Pep-24. It was also interesting to see how
a single-residue difference signiﬁcantly altered the cleavage efﬁ-
ciency of newly formed peptides by BoNT/E, for instance, Pep-28
(2%) versus Pep-29 (88%). In conclusion, this result demonstrated
that seven internal residues (RHMALDM) within the BoNT/E
peptide substrate seem to not participate in enzyme–substrate
interaction and, hence, can be removedwithout signiﬁcant negative
impact on the substrate cleavage. To examine the viability of
further shortening Pep-29, three new peptides (Pep-32, Pep-33,and Pep-34) were designed, where one to three C-terminal residues
(T, KT, and NKT) were removed but the terminal Arg residue was
maintained. It was observed that the shortest Pep-34 turned out
to be a poor BoNT/E substrate, whereas the medium-length sub-
strate, Pep-33, retained the most substrate capability (Table 3).
Pep-32, on the other hand, resulted in signiﬁcant activity improve-
ment compared with Pep-29. Pep-32 generated at least 30% more
CT and NT products than Pep-29, suggesting that Pep-32 possessed
a higher BoNT/E cleavage efﬁciency, whereas the ionization efﬁ-
ciency of its CT product remained unchanged. This peptide was
then used as a new template for additional optimization discussed
below.
Further improvement accomplished by single or multiple substitutions
Based on the sequence of the best substrate, Pep-32, we carried
out a thorough single mutation study where every single residue
was substituted with selected amino acids and the peptide
mutants were tested as BoNT/E substrates. Whereas approximately
two-thirds of the mutants tested produced less cleavage products
than the wild type, another one-third of the single mutated pep-
tides resulted in a higher substrate efﬁciency, with some of those
showing 3-fold or higher improvement (Fig. 1), demonstrating
the power of a mutation approach for substrate optimization.
It was interesting to observe that a substantial improvement
was accomplished when each of three N-terminal nonpolar Ile res-
idues was replaced by a Phe residue bearing a more hydrophobic
side chain. These data emphasized our speculation described above
that the N-terminal residues might be involved in direct contact
with the catalytic domain of the toxin via hydrophobic–hydropho-
bic interactions. Substitution with even stronger hydrophobic resi-
dues probably enhanced such interaction and, therefore, increased
substrate binding afﬁnity. To explore whether those putative
interactions can be further improved, a series of peptides with the
modiﬁcations of hydrophobic residues in the N-terminal region of
Pep-32 were developed (Fig. 2A). A slight increase in detected CT
product was observed as the six N-terminal residues were replaced
by three Phe residues in Pep-35. On the other hand, reduced detec-
tion of CT product resulted when one more Phe residue was added
in Pep-36. This suggested that three hydrophobic residues still
retained the special enzyme–substrate interaction, even in a
shorter peptide, but the contact might be affected by a longer
hydrophobic chain. When the three N-terminal Ile residues in
Pep-32 were replaced by residues with a more hydrophobic struc-
ture, such as Phe in Pep-37, Trp in Pep-40, and 1-naphthylalanine
(1-Nal) in Pep-42, all new peptides acted as better substrates. In
Fig. 1. Effect of single amino acid mutations on the detection of cleavage product of
mutated Pep-32 by BoNT/E. The residues at the BoNT/E cleavage site are underlined.
X represents norleucine.
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seems proportional to the size of the bulky side chain groups
(1-Nal > Trp > Phe; see Fig. 2B). These data provided additional
supportive evidence for the suggestion of a hydrophobic interactionFig. 2. (A) Cleavage efﬁciency of the peptides modiﬁed with N-terminal hydrophobic res
represented by letters, and other identical regions of the sequences are represented bybetween the BoNT/E enzyme and the peptide substrates. Moreover,
the hydrophobicity effect was also demonstrated by the fact that
the double Trp substitution (Pep-39) displayed higher cleavage
efﬁciency than the triple Phe substituted peptide (Pep-37), and
the triple Trp replacement in Pep-40 resulted in better substrate
efﬁciency than the double-Trp one in Pep-39, presumably due to
the difference of their combined hydrophobicity. A similar effect
was also observed by comparing the cleavage of the double 1-Nal
peptide (Pep-41) with that of the triple Trp and triple 1-Nal pep-
tides (Pep-40 and Pep-42, respectively). Furthermore, signiﬁcantly
reduced substrate cleavage by BoNT/E on the peptides with a clus-
ter of ﬁve Phe residues (Pep-38) or four 1-Nal residues (Pep-43)
suggested that the size of the hydrophobic cluster on the N termi-
nus of a substrate was not unrestricted. In other words, the space
of the putative hydrophobic pocket in the catalytic domain of the
toxin was limited and might not allow the placement of more than
three very bulky side chain groups. More study is needed to further
conﬁrm or address this proposed hydrophobic interaction between
BoNT/E protease and its peptide substrate.
Additional effort on further substrate optimization was put on
combining single mutations that showed enhanced detection of
BoNT/E cleavage products. Because some single mutations may
alter the conformation of mutated peptides or intra- and inter-
molecular interactions, and hence the property of their substrate
binding and/or catalysis, it is not realistic to expect that a bestidues. (B) Structure of some hydrophobic residues. Several N-terminal residues are
lines. O1, 1-naphthylalanine (1-Nal).
Table 4
Effect of multiple mutations on cleavage of modiﬁed peptides by BoNT/E toxin.
Note. Red letters represent the residues not present in the original SNAP-25 sequence. Bold letters represent the residues at the BoNT/E cleavage site. hR, homoarginine; O1,
1-Nal; O2, 2-Nal. (For interpretation of the reference to color in this table note, the reader is referred to the Web version of this article.)
Table 5
Comparison of cleavage of currently used and newly developed peptide substrates by
BoNT/E.
Peptide BoNT/E Product (area
ratio)
Relative
product
Type Activity
(mLD50)a
Pep-8 Not 100 0.40 1
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sequence all good single substitutions derived from the studies
described above. However, it is reasonable to believe that some
combinations of the single mutations may achieve an augmented
effect. For this purpose, new peptides were designed where differ-
ent combinations of the amino acid substitutions, derived from the
studies of single mutation and N-terminal modiﬁcations described
above, were incorporated into their corresponding positions of the
template peptide (Pep-32). In addition, some unnatural amino
acids, such as homoarginine, and terminal modiﬁcations, such as
C-terminal amidation, were introduced in some peptides in order
to increase peptide stability and reduce their susceptibility to non-
speciﬁc cleavage by other proteases (e.g., trypsin) present in bio-
logical samples. Table 4 lists some of these modiﬁed peptides
(Pep-45 to Pep-62) that showed a comparable or better substrate
performance than that of the peptide with a single internal substi-
tution (Pep-44). Whereas some multiple substituted peptides (e.g.,
Pep-45, Pep-46, Pep-48, Pep-55) exhibited similar or slightly
improved detection sensitivity, in terms of the detection of the
C-terminal cleavage products, many of the novel peptides achieved
a signiﬁcant improvement with 50% to 300% increase in the CT
product detection, revealing that an added beneﬁt on assay sensi-
tivity could be obtained by combining sound single mutations.
Among four candidates displaying 3-fold improvement over Pep-
44, Pep-59 proved to be the best in solubility and Pep-62 showed
the highest resistance toward undesired cleavage by nonspeciﬁc
proteases present in clinical samples (data not shown). The substi-
tution of the arginine at the cleavage site with an unnatural homo-
arginine residue seems to contribute to improved resistance
toward the cleavage by nonspeciﬁc proteases such as trypsin.
Therefore, these two optimal peptides were selected to be used
in further experiments and in routine analysis of biological sam-
ples for BoNT/E detection by the Endopep–MS assay.activated
Pep-59 Not
activated
1 2.35 581
Pep-8 Activated 0.16 1.07 1
Pep-59 Activated 0.0016 5.48 511
a The speciﬁc activities of activated and not-activated BoNT/E was provided by
the manufacturer. Cleavage reactions were conducted at 37 C for 1 h.Evaluation of optimized peptides as BoNT/E substrates in Endopep–MS
assay
To evaluate the outcome of the optimization for the BoNT/E
substrates, Pep-59, one of the four best optimized peptides, wascompared with Pep-8, the substrate currently used in the Endo-
pep–MS assay. The substrates were hydrolyzed by two forms of
BoNT/E toxins; one is the single-chain holotoxin without preacti-
vation as a complex with neurotoxin-associated proteins, and the
other is the BoNT/E di-chain complex that had been activated by
exposing it to trypsin during the manufacturing process. As shown
in Table 5, the optimal peptide was able to detect the cleavage
products at a 500-fold lower level of BoNT/E compared with the
old peptide substrate, for both not-trypsin-activated and trypsin-
activated BoNT/E toxin complexes, under the same experimental
conditions, demonstrating a dramatic improvement in the assay
sensitivity using the new peptide substrate. When testing the sen-
sitivity of the Endopep–MS assay using the newly developed opti-
mal peptide, a limit of detection of 0.1 mLD50 (1 pg/ml or 5.5 amol/
ml) was accomplished for the detection of not-trypsin-activated
BoNT/E toxin complex spiked in serum and stool extract, two com-
mon biological matrices used for botulism clinical samples, after a
4-h cleavage reaction (Fig. 3, signal/noise [S/N] > 3). This repre-
sents an assay sensitivity 10-fold lower than that measured by a
traditional mouse bioassay. The speciﬁcity of the optimal peptides
was examined by exposing them to other serotypes of botulinum
neurotoxins, including types A, B, and F, and no cleavage product
was observed (data not shown). In addition to the speciﬁc BoNT/
E subtype (E3) used in the experiments described above, the
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Fig. 3. Product response from the cleavage of Pep-59 by not-trypsin-activated
BoNT/E of various concentrations spiked in serum and stool matrices. Cleavage
reaction conditions: 37 C, 4 h.
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tested BoNT/E subtypes, including E1, E2, E4, E7, and the most
divergent E9 (data not shown).
Conclusion
We developed novel peptide substrates for the mass spectrom-
etry-based Endopep–MS assay for the detection of type E botu-
linum neurotoxin. The systematic and comprehensive
optimization process included peptide terminal truncation, inter-
nal deletion, single and multiple substitution, terminal residue
modiﬁcation, and incorporation of unnatural amino acid residues.
Our data demonstrate that one of the four optimal peptides dem-
onstrated a 500-fold improvement in assay sensitivity over the
current substrate used for the detection of both not-trypsin-acti-
vated and trypsin-activated BoNT/E toxin complexes. The limit of
detection for the toxin complex without preactivation in serum,
stool, and food samples using the new substrate is 0.1 mouse LD50/
ml. In addition, the troublesome nonspeciﬁc cleavage in blank con-
trol samples was signiﬁcantly improved by incorporating an
unnatural homoarginine residue in the cleavage site of the optimal
peptides. A patent application for these optimized peptides has
been ﬁled, and the novel peptide substrates continue to be used
in our laboratory for routine analysis of clinical samples.
Disclaimer
The ﬁndings and conclusions in this article are those of the
authors and do not necessarily represent the ofﬁcial position of
the Centers for Disease Control and Prevention.
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